Alcobra Ltd. (ADHD):
Alcobra Ltd. (ADHD) ended its previous trading session at $1.51 with the Gain of 18.9%. The company’s market cap is $40.18 Million, and the average volume is $339.83 Million. The 52-Week High range of the stock is $2.58, while the 52-week low range is $0.83. The Price to Sales (P/S) of the stock is 0, while P/B (Price to Book) stands at 1.02. When we look at the Volatility of the company, Week Volatility is at 20.32% whereas Month Volatility is at 11.38%.
For the ongoing Fiscal Quarter, 2 analysts have an average earnings forecast of $-0.22 per share. According to the Analysts, the Low Earnings estimate for the current quarter is $-0.36, while the High earnings estimate is $-0.07.Comparatively, EPS for the same quarter last year was $-0.2.
According to 1 analysts, the Average Revenue Estimate for the current Fiscal quarter is $0 and the Low Revenue estimate is $0, while the High Revenue estimate is $0.
Alcobra Ltd. (ADHD) analysts on average have given a price target of $1.67 on ADHD stock.
According to the Recommendation Trends of the stock polled by Zacks Investment Research for this month, the company has a consensus recommendation of 3.33 out of the scale from 1 to 5 where 1 stands for Strong Buy and 5 means Strong Sell.
Concert Pharmaceuticals, Inc. (CNCE):
Concert Pharmaceuticals, Inc. (CNCE) shares Jumped 18.19% and ended the day at $16.5. Its 52-week high and low range is between $19.11 and $7.11. The company’s outstanding shares are 23.33 Million. The volume of the company in the last trading session was 1.32 Million. The stock has a market cap of 384.95 Million. The Stock shows P/E value of 0 and Forward P/E of 0.
According to Finviz reported data, The SMA20 of the stock is at 11.49%, SMA50 is 12.02 percent, while SMA200 is 19.13%. The stock is currently has its Return on Assets (ROA) value of -48.5 Percent. The Return on Investment and Return on Equity (ROE) values are -59.8 percent and -62 percent, respectively.
The company’s ATR (Average True Range) is 0.76. The Weekly Volatility is 7.51% and the Monthly Volatility is 4.70%.
When we look at the Analyst Recommendations of the stock, the company has 1 rating given by Analysts where 1 stands for Strong Buy and 5 stands for Strong Sell.
Concert Pharmaceuticals, Inc. (CNCE) analysts on average have given a price target of $1.67 on CNCE stock.
Concert Pharmaceuticals, Inc.’s Average Earnings Estimate for the current quarter is $-0.73, according to consensus of 3 analysts. The low EPS estimate is $-1.02, while the high EPS estimate is $-0.58.
Average Revenue Estimate of the company for the current Fiscal Quarter is $40000, according to consensus of 3 analysts. The higher end of the revenue estimate is $100000 and the lower end is $0.